CN106334065A - 一种治疗妇科疾病及具有美容作用的药食两用中药配方及生产工艺 - Google Patents
一种治疗妇科疾病及具有美容作用的药食两用中药配方及生产工艺 Download PDFInfo
- Publication number
- CN106334065A CN106334065A CN201610896099.7A CN201610896099A CN106334065A CN 106334065 A CN106334065 A CN 106334065A CN 201610896099 A CN201610896099 A CN 201610896099A CN 106334065 A CN106334065 A CN 106334065A
- Authority
- CN
- China
- Prior art keywords
- parts
- chinese medicine
- medicinal
- medicine formula
- edible
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 36
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims abstract description 27
- 201000010099 disease Diseases 0.000 title claims abstract description 26
- 230000000694 effects Effects 0.000 title abstract description 14
- 230000003796 beauty Effects 0.000 title abstract description 5
- 238000004519 manufacturing process Methods 0.000 title description 4
- 240000001811 Dioscorea oppositifolia Species 0.000 claims abstract description 15
- 235000002722 Dioscorea batatas Nutrition 0.000 claims abstract description 14
- 235000006536 Dioscorea esculenta Nutrition 0.000 claims abstract description 14
- 235000003416 Dioscorea oppositifolia Nutrition 0.000 claims abstract description 14
- 241000756943 Codonopsis Species 0.000 claims abstract description 13
- 244000179560 Prunella vulgaris Species 0.000 claims abstract description 13
- 235000005187 Taraxacum officinale ssp. officinale Nutrition 0.000 claims abstract description 11
- 240000001949 Taraxacum officinale Species 0.000 claims abstract description 4
- 239000007788 liquid Substances 0.000 claims description 19
- 235000008113 selfheal Nutrition 0.000 claims description 11
- 235000008216 herbs Nutrition 0.000 claims description 10
- 239000000463 material Substances 0.000 claims description 10
- 239000002775 capsule Substances 0.000 claims description 9
- 238000000605 extraction Methods 0.000 claims description 9
- 239000012467 final product Substances 0.000 claims description 9
- 239000012535 impurity Substances 0.000 claims description 9
- 239000003826 tablet Substances 0.000 claims description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 9
- 239000000203 mixture Substances 0.000 claims description 8
- 238000002360 preparation method Methods 0.000 claims description 7
- 239000002994 raw material Substances 0.000 claims description 7
- 239000008187 granular material Substances 0.000 claims description 6
- 238000002156 mixing Methods 0.000 claims description 5
- 238000009835 boiling Methods 0.000 claims description 4
- 238000000034 method Methods 0.000 claims description 4
- 238000011049 filling Methods 0.000 claims description 3
- 238000001914 filtration Methods 0.000 claims description 3
- 238000009472 formulation Methods 0.000 claims description 3
- 238000012856 packing Methods 0.000 claims description 3
- 239000002245 particle Substances 0.000 claims description 3
- 238000001035 drying Methods 0.000 claims description 2
- 208000002193 Pain Diseases 0.000 abstract description 27
- 230000006870 function Effects 0.000 abstract description 18
- 210000005075 mammary gland Anatomy 0.000 abstract description 15
- 210000000952 spleen Anatomy 0.000 abstract description 15
- 210000004185 liver Anatomy 0.000 abstract description 12
- 206010013935 Dysmenorrhoea Diseases 0.000 abstract description 10
- 230000007958 sleep Effects 0.000 abstract description 10
- 206010006272 Breast mass Diseases 0.000 abstract description 7
- 238000011282 treatment Methods 0.000 abstract description 7
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 abstract description 6
- 206010022437 insomnia Diseases 0.000 abstract description 6
- 206010022998 Irritability Diseases 0.000 abstract description 4
- 210000001835 viscera Anatomy 0.000 abstract description 4
- 230000005906 menstruation Effects 0.000 abstract description 3
- 230000002159 abnormal effect Effects 0.000 abstract description 2
- 235000010674 Prunella vulgaris Nutrition 0.000 abstract 1
- 206010046798 Uterine leiomyoma Diseases 0.000 abstract 1
- VQLYBLABXAHUDN-UHFFFAOYSA-N bis(4-fluorophenyl)-methyl-(1,2,4-triazol-1-ylmethyl)silane;methyl n-(1h-benzimidazol-2-yl)carbamate Chemical compound C1=CC=C2NC(NC(=O)OC)=NC2=C1.C=1C=C(F)C=CC=1[Si](C=1C=CC(F)=CC=1)(C)CN1C=NC=N1 VQLYBLABXAHUDN-UHFFFAOYSA-N 0.000 abstract 1
- 230000003750 conditioning effect Effects 0.000 abstract 1
- 238000009499 grossing Methods 0.000 abstract 1
- 206010020718 hyperplasia Diseases 0.000 abstract 1
- 230000003867 tiredness Effects 0.000 abstract 1
- 208000016255 tiredness Diseases 0.000 abstract 1
- 210000000481 breast Anatomy 0.000 description 20
- 239000000047 product Substances 0.000 description 20
- 201000010260 leiomyoma Diseases 0.000 description 14
- 230000036541 health Effects 0.000 description 12
- 230000035755 proliferation Effects 0.000 description 12
- 210000004072 lung Anatomy 0.000 description 11
- 230000008961 swelling Effects 0.000 description 8
- 241000245665 Taraxacum Species 0.000 description 7
- 210000003734 kidney Anatomy 0.000 description 7
- 229940079593 drug Drugs 0.000 description 6
- 210000002784 stomach Anatomy 0.000 description 6
- 238000005728 strengthening Methods 0.000 description 6
- 206010012735 Diarrhoea Diseases 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 230000007774 longterm Effects 0.000 description 5
- 206010008570 Chloasma Diseases 0.000 description 4
- 208000003351 Melanosis Diseases 0.000 description 4
- 206010016256 fatigue Diseases 0.000 description 4
- 206010010774 Constipation Diseases 0.000 description 3
- 206010011224 Cough Diseases 0.000 description 3
- 208000037093 Menstruation Disturbances Diseases 0.000 description 3
- 206010027339 Menstruation irregular Diseases 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 235000009508 confectionery Nutrition 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 235000019634 flavors Nutrition 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 230000003821 menstrual periods Effects 0.000 description 3
- 231100000614 poison Toxicity 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- BAHMQESJBKGPTE-UHFFFAOYSA-N 1,5,8-trimethyl-3a,4-dihydroazuleno[6,5-b]furan-2,6-dione Chemical compound C1C2OC(=O)C(C)=C2C=C2C(C)=CC(=O)C2=C1C BAHMQESJBKGPTE-UHFFFAOYSA-N 0.000 description 2
- 206010000060 Abdominal distension Diseases 0.000 description 2
- 206010006298 Breast pain Diseases 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 206010062717 Increased upper airway secretion Diseases 0.000 description 2
- 102000014150 Interferons Human genes 0.000 description 2
- 108010050904 Interferons Proteins 0.000 description 2
- 206010023126 Jaundice Diseases 0.000 description 2
- 208000006662 Mastodynia Diseases 0.000 description 2
- 208000004880 Polyuria Diseases 0.000 description 2
- 206010036790 Productive cough Diseases 0.000 description 2
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 210000000038 chest Anatomy 0.000 description 2
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 2
- 229960001231 choline Drugs 0.000 description 2
- 230000004087 circulation Effects 0.000 description 2
- VEVZSMAEJFVWIL-UHFFFAOYSA-O cyanidin cation Chemical compound [O+]=1C2=CC(O)=CC(O)=C2C=C(O)C=1C1=CC=C(O)C(O)=C1 VEVZSMAEJFVWIL-UHFFFAOYSA-O 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 230000035619 diuresis Effects 0.000 description 2
- 230000004064 dysfunction Effects 0.000 description 2
- 201000006549 dyspepsia Diseases 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 238000005469 granulation Methods 0.000 description 2
- 230000003179 granulation Effects 0.000 description 2
- 210000002216 heart Anatomy 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 229940079322 interferon Drugs 0.000 description 2
- 235000021266 loss of appetite Nutrition 0.000 description 2
- 208000004396 mastitis Diseases 0.000 description 2
- 208000026435 phlegm Diseases 0.000 description 2
- 239000002574 poison Substances 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 208000024794 sputum Diseases 0.000 description 2
- 210000003802 sputum Anatomy 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- LHXDLQBQYFFVNW-XCBNKYQSSA-N (+)-Fenchone Natural products C1C[C@]2(C)C(=O)C(C)(C)[C@H]1C2 LHXDLQBQYFFVNW-XCBNKYQSSA-N 0.000 description 1
- OILXMJHPFNGGTO-UHFFFAOYSA-N (22E)-(24xi)-24-methylcholesta-5,22-dien-3beta-ol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(C)C(C)C)C1(C)CC2 OILXMJHPFNGGTO-UHFFFAOYSA-N 0.000 description 1
- WCGUUGGRBIKTOS-GPOJBZKASA-N (3beta)-3-hydroxyurs-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C)[C@H](C)[C@H]5C4=CC[C@@H]3[C@]21C WCGUUGGRBIKTOS-GPOJBZKASA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- MIJYXULNPSFWEK-GTOFXWBISA-N 3beta-hydroxyolean-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C MIJYXULNPSFWEK-GTOFXWBISA-N 0.000 description 1
- OQMZNAMGEHIHNN-UHFFFAOYSA-N 7-Dehydrostigmasterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CC(CC)C(C)C)CCC33)C)C3=CC=C21 OQMZNAMGEHIHNN-UHFFFAOYSA-N 0.000 description 1
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 description 1
- 239000004382 Amylase Substances 0.000 description 1
- 102000013142 Amylases Human genes 0.000 description 1
- 108010065511 Amylases Proteins 0.000 description 1
- JMGZEFIQIZZSBH-UHFFFAOYSA-N Bioquercetin Natural products CC1OC(OCC(O)C2OC(OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5)C(O)C2O)C(O)C(O)C1O JMGZEFIQIZZSBH-UHFFFAOYSA-N 0.000 description 1
- 241000208671 Campanulaceae Species 0.000 description 1
- 102000030523 Catechol oxidase Human genes 0.000 description 1
- 108010031396 Catechol oxidase Proteins 0.000 description 1
- 235000008495 Chrysanthemum leucanthemum Nutrition 0.000 description 1
- 244000192528 Chrysanthemum parthenium Species 0.000 description 1
- 235000000604 Chrysanthemum parthenium Nutrition 0.000 description 1
- 241000723346 Cinnamomum camphora Species 0.000 description 1
- WCNPJVPXLWJQIR-HKSFMPNISA-N Codonopsine Chemical compound C1=C(OC)C(OC)=CC=C1[C@H]1N(C)[C@H](C)[C@@H](O)[C@@H]1O WCNPJVPXLWJQIR-HKSFMPNISA-N 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- GCPYCNBGGPHOBD-UHFFFAOYSA-N Delphinidin Natural products OC1=Cc2c(O)cc(O)cc2OC1=C3C=C(O)C(=O)C(=C3)O GCPYCNBGGPHOBD-UHFFFAOYSA-N 0.000 description 1
- 206010012335 Dependence Diseases 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- JKLISIRFYWXLQG-UHFFFAOYSA-N Epioleonolsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4CCC3C21C JKLISIRFYWXLQG-UHFFFAOYSA-N 0.000 description 1
- 206010016322 Feeling abnormal Diseases 0.000 description 1
- 206010017553 Furuncle Diseases 0.000 description 1
- 206010018612 Gonorrhoea Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- OVSQVDMCBVZWGM-SJWGPRHPSA-N Hyperin Natural products O[C@H]1[C@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=C(C=2C=C(O)C(O)=CC=2)OC2=CC(O)=CC(O)=C2C1=O OVSQVDMCBVZWGM-SJWGPRHPSA-N 0.000 description 1
- FVQOMEDMFUMIMO-UHFFFAOYSA-N Hyperosid Natural products OC1C(O)C(O)C(CO)OC1OC1C(=O)C2=C(O)C=C(O)C=C2OC1C1=CC=C(O)C(O)=C1 FVQOMEDMFUMIMO-UHFFFAOYSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000008771 Lymphadenopathy Diseases 0.000 description 1
- 206010028372 Muscular weakness Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- YBRJHZPWOMJYKQ-UHFFFAOYSA-N Oleanolic acid Natural products CC1(C)CC2C3=CCC4C5(C)CCC(O)C(C)(C)C5CCC4(C)C3(C)CCC2(C1)C(=O)O YBRJHZPWOMJYKQ-UHFFFAOYSA-N 0.000 description 1
- MIJYXULNPSFWEK-UHFFFAOYSA-N Oleanolinsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4=CCC3C21C MIJYXULNPSFWEK-UHFFFAOYSA-N 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- 208000012287 Prolapse Diseases 0.000 description 1
- 208000001431 Psychomotor Agitation Diseases 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- 241001093501 Rutaceae Species 0.000 description 1
- IKGXIBQEEMLURG-UHFFFAOYSA-N Rutin Chemical compound OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- HZYXFRGVBOPPNZ-UHFFFAOYSA-N UNPD88870 Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)=CCC(CC)C(C)C)C1(C)CC2 HZYXFRGVBOPPNZ-UHFFFAOYSA-N 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 208000002495 Uterine Neoplasms Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 208000019790 abdominal distention Diseases 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 229960000458 allantoin Drugs 0.000 description 1
- LHXDLQBQYFFVNW-UHFFFAOYSA-N alpha-fenchone Natural products C1CC2(C)C(=O)C(C)(C)C1C2 LHXDLQBQYFFVNW-UHFFFAOYSA-N 0.000 description 1
- 235000019418 amylase Nutrition 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000001142 anti-diarrhea Effects 0.000 description 1
- 210000000436 anus Anatomy 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 230000004596 appetite loss Effects 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- LGJMUZUPVCAVPU-UHFFFAOYSA-N beta-Sitostanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 LGJMUZUPVCAVPU-UHFFFAOYSA-N 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 229930008380 camphor Natural products 0.000 description 1
- 229960000846 camphor Drugs 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000002279 cholagogic effect Effects 0.000 description 1
- WCNPJVPXLWJQIR-UHFFFAOYSA-N codonopsine Natural products C1=C(OC)C(OC)=CC=C1C1N(C)C(C)C(O)C1O WCNPJVPXLWJQIR-UHFFFAOYSA-N 0.000 description 1
- 235000007336 cyanidin Nutrition 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 235000007242 delphinidin Nutrition 0.000 description 1
- JKHRCGUTYDNCLE-UHFFFAOYSA-O delphinidin Chemical compound [O+]=1C2=CC(O)=CC(O)=C2C=C(O)C=1C1=CC(O)=C(O)C(O)=C1 JKHRCGUTYDNCLE-UHFFFAOYSA-O 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000009429 distress Effects 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 230000005059 dormancy Effects 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 208000022532 enlargement of lymph nodes Diseases 0.000 description 1
- IVTMALDHFAHOGL-UHFFFAOYSA-N eriodictyol 7-O-rutinoside Natural products OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C=C3C(C(C(O)=C(O3)C=3C=C(O)C(O)=CC=3)=O)=C(O)C=2)O1 IVTMALDHFAHOGL-UHFFFAOYSA-N 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 229930006735 fenchone Natural products 0.000 description 1
- 235000008384 feverfew Nutrition 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 208000001786 gonorrhea Diseases 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000011132 hemopoiesis Effects 0.000 description 1
- NQYPTLKGQJDGTI-FCVRJVSHSA-N hyperoside Natural products OC[C@H]1O[C@@H](OC2=C(Oc3cc(O)cc(O)c3[C@H]2O)c4ccc(O)c(O)c4)[C@H](O)[C@@H](O)[C@H]1O NQYPTLKGQJDGTI-FCVRJVSHSA-N 0.000 description 1
- 230000001077 hypotensive effect Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000016507 interphase Effects 0.000 description 1
- 239000008141 laxative Substances 0.000 description 1
- 230000002475 laxative effect Effects 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 201000005630 leukorrhea Diseases 0.000 description 1
- 208000019017 loss of appetite Diseases 0.000 description 1
- 201000007227 lymph node tuberculosis Diseases 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 208000007106 menorrhagia Diseases 0.000 description 1
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 229940100243 oleanolic acid Drugs 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 230000027758 ovulation cycle Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- HZLWUYJLOIAQFC-UHFFFAOYSA-N prosapogenin PS-A Natural products C12CC(C)(C)CCC2(C(O)=O)CCC(C2(CCC3C4(C)C)C)(C)C1=CCC2C3(C)CCC4OC1OCC(O)C(O)C1O HZLWUYJLOIAQFC-UHFFFAOYSA-N 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- OVSQVDMCBVZWGM-DTGCRPNFSA-N quercetin 3-O-beta-D-galactopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=C(C=2C=C(O)C(O)=CC=2)OC2=CC(O)=CC(O)=C2C1=O OVSQVDMCBVZWGM-DTGCRPNFSA-N 0.000 description 1
- FDRQPMVGJOQVTL-UHFFFAOYSA-N quercetin rutinoside Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 FDRQPMVGJOQVTL-UHFFFAOYSA-N 0.000 description 1
- BBFYUPYFXSSMNV-UHFFFAOYSA-N quercetin-7-o-galactoside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC(O)=C2C(=O)C(O)=C(C=3C=C(O)C(O)=CC=3)OC2=C1 BBFYUPYFXSSMNV-UHFFFAOYSA-N 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- IKGXIBQEEMLURG-BKUODXTLSA-N rutin Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@@H]1OC[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-BKUODXTLSA-N 0.000 description 1
- ALABRVAAKCSLSC-UHFFFAOYSA-N rutin Natural products CC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5 ALABRVAAKCSLSC-UHFFFAOYSA-N 0.000 description 1
- 235000005493 rutin Nutrition 0.000 description 1
- 229960004555 rutoside Drugs 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 208000013220 shortness of breath Diseases 0.000 description 1
- 230000003860 sleep quality Effects 0.000 description 1
- 235000015096 spirit Nutrition 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- HCXVJBMSMIARIN-PHZDYDNGSA-N stigmasterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)/C=C/[C@@H](CC)C(C)C)[C@@]1(C)CC2 HCXVJBMSMIARIN-PHZDYDNGSA-N 0.000 description 1
- 229940032091 stigmasterol Drugs 0.000 description 1
- BFDNMXAIBMJLBB-UHFFFAOYSA-N stigmasterol Natural products CCC(C=CC(C)C1CCCC2C3CC=C4CC(O)CCC4(C)C3CCC12C)C(C)C BFDNMXAIBMJLBB-UHFFFAOYSA-N 0.000 description 1
- 235000016831 stigmasterol Nutrition 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 229930183580 tangshenoside Natural products 0.000 description 1
- GGGUGZHBAOMSFJ-GADYQYKKSA-N taraxerol Chemical compound CC([C@@H]1CC2)(C)[C@@H](O)CC[C@]1(C)[C@@H]1[C@]2(C)C2=CC[C@@]3(C)CCC(C)(C)C[C@H]3[C@]2(C)CC1 GGGUGZHBAOMSFJ-GADYQYKKSA-N 0.000 description 1
- HYTFUKZLSYXRDX-UHFFFAOYSA-N taraxerol Natural products CC1CCCC2C3(C)CCC4(C)C5CC(C)(C)CCC5(C)C=CC4(C)C3C(O)CC12C HYTFUKZLSYXRDX-UHFFFAOYSA-N 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 150000008130 triterpenoid saponins Chemical class 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 208000019206 urinary tract infection Diseases 0.000 description 1
- 229940096998 ursolic acid Drugs 0.000 description 1
- PLSAJKYPRJGMHO-UHFFFAOYSA-N ursolic acid Natural products CC1CCC2(CCC3(C)C(C=CC4C5(C)CCC(O)C(C)(C)C5CCC34C)C2C1C)C(=O)O PLSAJKYPRJGMHO-UHFFFAOYSA-N 0.000 description 1
- 206010046766 uterine cancer Diseases 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 206010046901 vaginal discharge Diseases 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 230000002087 whitening effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/894—Dioscoreaceae (Yam family)
- A61K36/8945—Dioscorea, e.g. yam, Chinese yam or water yam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/288—Taraxacum (dandelion)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/34—Campanulaceae (Bellflower family)
- A61K36/344—Codonopsis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/536—Prunella or Brunella (selfheal)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/752—Citrus, e.g. lime, orange or lemon
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明公开了一种治疗妇科疾病及具有美容作用的药食两用中药配方,其特征在于:其包含下述原料,按重量份数计:山药5~20份、夏枯草5~40份、党参5~30份、蒲公英5~20份、陈皮5~20份。本发明功能主治:软坚散结,消肿止痛,舒肝健脾,祛斑美容,调理各脏腑功能。用于治疗乳腺增生,乳腺结节,子宫肌瘤、月经不调、痛经、身倦乏力、烦燥易怒、失眠多梦、面色失华易长斑等。
Description
技术领域
本发明涉及一种药物的配方及生产工艺,特别涉及一种治疗乳腺增生、乳腺结节、痛经、子宫肌瘤以及具有美容作用的中药配方及生产工艺。
背景技术
由于生活、工作节奏加快,加上食品、气候、环境等因素影响,乳腺增生、乳腺结节、痛经、子宫肌瘤、身体易疲劳、失眠多梦、烦躁易怒、面色无华易长斑等疾病的发病率呈明显上升趋势,成为现代女性健康的头号大敌,如果采取不当的治疗方式甚至会发展成为乳腺癌、子宫癌等,严重损害患者身体健康。治疗该类疾病的方法归结起来一类是服用药品,另一类是服用有辅助治疗作用的保健品以及手术治疗。研究表明乳腺增生、乳腺结节、痛经、子宫肌瘤、脸上易长斑等疾病是因为人体内环境改变导致内分泌紊乱长期积累而产生病变,要进行彻底治疗也需要长期服药。俗话说“是药三分毒”,长期服药必将会对患者的肝肾等功能造成不良影响;一般的保健产品也仅仅能起到辅助的保健作用而预防和治疗作用差;手术治疗又会给患者身心上带来巨大痛苦。
山药:为薯蓣科植物薯蓣Dioscorea opposita Thunb. 的干燥根茎。山药含薯蓣皂苷、粘液蛋白、多糖、尿囊素、淀粉酶、多酚氧化酶、维生素、微量元素等多种有益成分。
性味甘、平,归脾、肺、肾经。具有补脾养胃,生津益肺,补肾涩精的功能;能诱导产生干扰素,增强人体免疫功能,其所含胆碱和卵磷脂有助于提高人的记忆力,常食可健身强体、延缓衰老等功效,主要用于脾虚食少、泄泻便溏、白带过多、诸虚百损、疗五劳七伤、去头面游风、止腰痛、除烦热、补心气不足、开达心孔、多记事、益肾气、健脾胃、止泻痢、润毛皮,生捣贴肿、硬毒能治。
夏枯草:为唇形科植物夏枯草Prunella vulgaris L.的干燥果穗。性味辛、苦、寒,归肝、胆经。具有清肝泻火,明目,散结消肿的功能,含三萜皂苷、芸香苷、金丝桃苷、熊果酸、咖啡酸、游离齐敦果酸、飞燕草素、矢车菊素、d-樟脑、d-小茴香酮等。传统上主要用于治疗目赤肿痛、头痛、眩晕,药理研究有降血压作用,现代临床用以治疗高血压病,有助降压;取其散结消肿而常用治甲状腺肿大、淋巴结肿大、乳痈、乳癖、乳房胀痛、乳腺增生、高血压等属于肝热者。
党参:为桔梗科植物党参Codonopsis pilosula (Franch.) Nannf.的干燥根。性味甘、平,归脾、肺经。具有健脾益肺,养血生津的功能,并有增强免疫力、扩张血管、降压、改善微循环、增强造血功能等作用。主要用于脾肺气虚,食少倦怠,咳嗽虚喘,气血不足,面色萎黄,心悸气短,津伤口渴,内热消渴,脾虚食少便溏,四肢无力,心悸,气短,口干,自汗,脱肛,阴挺。党参含党参苷、多糖、豆甾醇、蒲公英萜醇、党参碱、苍术内酯。
蒲公英:为菊科植物蒲公英Taraxacum mongolicum Hand.-Mazz.的干燥全草。性味苦、甘、寒,归肝、胃经。具有清热解毒,消肿散结,利尿通淋的功能;能诱导产生干扰素,增强人体免疫功能。含蒲公英醇、蒲公英素、胆碱、有机酸、菊糖等多种健康营养成分,有利尿、缓泻、退黄疸、利胆等功效,主要用于疔疮肿毒,乳痈,瘰疬,湿热黄疸,热淋涩痛,尿路感染等。
陈皮:陈皮为芸香科植物橘 Citrus reticulata Blanco 及其栽培变种的干燥成熟果皮。性温,味辛、味苦,入脾经、胃经、肺经。理气健脾,调中,燥湿,化痰。主治脾胃气滞之脘腹胀满或疼痛、消化不良。湿浊阻中之胸闷腹胀、纳呆便溏。痰湿壅肺之咳嗽气喘。用于胸脘胀满,食少吐泻,咳嗽痰多。同补药则补,同泻药则泻,同升药则升,同降药则降。
发明内容
本发明要解决的技术问题是:解决了单一处方对于相关疾病疗效不明显问题;本品通过将五味药材组合在一起,方中以夏枯草清肝泻火,解郁散结,消肿解毒为君药,蒲公英清热解毒,消肿散结,能散滞气为臣药,辅以健脾药以为佐使,山 药、党参、陈皮补其不足,清其虚热,行气止痛调中,因此在治疗相关疾病方面发生了质变性的突破,效果非常好,有效率达到95%以上。
本发明的技术方案是:一种治疗妇科疾病及具有美容作用的药食两用中药配方,其包含下述原料,按重量份数计:山药5~20份、夏枯草5~40份、党参5~30份、蒲公英5~20份、陈皮5~20。
优选的,其包含下述原料,按重量份数计:山药10~15份、夏枯草10~30份、党参5~20份、蒲公英5~15份、陈皮10~15份。
所述的药食两用的中药的剂型包括:颗粒剂、胶囊剂和片剂。
所述的颗粒剂制作步骤:按量称取以上五味药材,去除杂质后加水煎煮提取3次,3次的煎液分别过滤后合并,将合并后的煎液浓缩成浸膏,浸膏与辅料混匀制成颗粒并干燥,分装即得。
所述的胶囊剂制作:按量称取以上五味药材,去除杂质后加水煎煮提取3次, 3次的煎液分别过滤并合并,将合并后的煎液浓缩成浸膏,浸膏与辅料混匀、制粒、干燥后填充胶囊即得。
所述的片剂制作:按量称取以上五味药材,去除杂质后加水煎煮提取3次,煎液分别过滤并合并,将合并后的煎液浓缩成浸膏,浸膏与辅料混匀、制粒、干燥、压片即得。
本发明的有益效果:
功能主治:软坚散结,消肿止痛,舒肝健脾,祛斑美容,有效调理各脏腑功能。用于治疗乳腺增生,乳腺结节,子宫肌瘤、月经不调、痛经、身倦乏力、烦燥易怒、失眠多梦、面色失华易长斑等。
本产品特点:
1、乳腺增生、乳腺结节、子宫肌瘤、月经不调、痛经、身倦乏力、烦燥易怒、失眠多梦、面色失华易长斑等同属于肝郁气滞、痰湿阻络、冲任失调等导致的脏腑机能失调、气血失和造成,因此以上疾病也常常是伴随着相互交叉关联出现,给患者身心带来极大痛苦。
2、本发明配方严格根据中医中药理论五行相生相克的原理,从疾病的表象比如:乳腺增生、乳腺结节、痛经、子宫肌瘤、身体易疲劳、失眠多梦、烦躁易怒、面色无华易长斑等得出其实质是病在身体的脏腑机能失调、气血失和有关。所以治疗时取夏枯草、蒲公英清热解毒,清泻肝火,散结消肿,消炎杀菌之功;山药、党参、陈皮入脾、肺、胃、肾经,能健脾胃、益气养血、固肾益精。中医说“四季脾旺不受邪”“ 肺主中焦以贯四旁”,其机理是脾胃健康,心、肝、肺、肾均不易受邪;利用培土(脾胃)生金(肺),金(肺)胜制木(肝),来治疗肝气郁结。通过药物之间的相互作用,对肝、脾、肾等脏腑功能进行有效调理,达到软坚散结,消肿止痛,健脾益气、祛斑美容的目的。
3、以上药味看似简单,但是诸药合用,不但疗效确切,而且与市面上其它治疗此类疾病的药品相比,并没有一些药性峻猛、毒副作用大的配方,无耗气损血之弊,因此更适合广大的患者使用。
4、本产品组方所用的蒲公英、夏枯草、党参、山药、陈皮全部都是国家卫生部法定认可的药食两用食材,因此能长期服用而无其它同类产品带来的毒副作用和不良反应,所以本产品长期服用更安全。
5、服用本产品,通过药物之间相互作用对患者的各脏腑功能进行调理,使各脏腑功能恢复正常,达到改善和稳定患者人体内环境的目的,从而杜绝疾病再次发生,让患者彻底恢复健康。
本发明产品实际使用实例如下:
实例1:周家兰,46岁,经医院确诊为乳腺增生,子宫肌瘤。平时有乳房疼痛,月经不调,胃口不好,心烦意乱,脸上有黄褐斑。服用本产品半月后,疼痛减轻,胃口有所改善。继续服用1月后,乳房几乎不再疼痛,继续服用3月后,已无疼痛不适感,去医院B超检查,乳腺无增生。继续服用6个月后检查已无子宫肌瘤,脸上气色红润,黄褐斑变淡。
实例2:徐丽,30岁,痛经,每次生理期来的前一周下腹疼痛难忍,必须靠吃止痛药稍能缓解,严重影响工作和生活。服用本产品3周后,当月疼痛次数明显减少,疼痛程度明显减轻。经期结束后继续服用到下次生理周期到来,几乎没有出现疼痛。
实例3:李明慧:45岁,乳房胀痛,触摸有包块,经医院确诊为乳腺增生。服用本产品1月后感觉疼痛明显减轻,包块减小,心情舒畅。继续服用1月后乳房不再疼痛,触摸还有小包块,再服用1月后,乳房已无疼痛和包块,去医院检查已无乳腺增生。
实例4:王兰:47岁,子宫肌瘤已手术后3个月,感觉经前乳房胀痛、平时有心烦、失眠多梦、易疲劳、常有便秘发生。曾服用逍遥丸1个月感觉没有什么效果而停用。服用本产品半月后便秘减轻,服用1月后,已无便秘现象,乳房不再疼痛,睡眠好,继续服用1月后所有症状消失,心情愉快,气色好。
实例5:马玲:40岁,乳房单侧胀痛,经前期加重,脸色暗黄,皮肤粗糙。服用本产品1月后,乳房疼痛明显缓解,继续服用1月后,无疼痛现象。为巩固疗效继续再服用1个月,痊愈,皮肤逐渐变得细腻有光泽。
实例6:吴小梅,35岁,一侧乳房时有疼痛,触摸有一条索状肿块,易怒,单位体检时发现约有0.6*0.8cm大小的子宫肌瘤。服用本品1月后乳房疼痛明显缓解,继续服用1月后,条索状肿块范围减小,再服用1月后,乳房无疼痛。肿块变小,间断服药6个月,检查发现已无子宫肌瘤,皮肤白皙有弹性。
实例7:袁丽珍,46岁,乳房胀痛,情绪不好时疼痛加重。失眠多梦,脸上黄褐斑明显,常有口气。服用本品1月后乳房胀痛减轻,睡眠改善。继续服用1月后乳房基本不痛,睡眠好。继续服用1个月,乳房不再疼痛,脸上部分黄褐斑减淡。
病例8:彭明会,40岁,痛经,子宫肌瘤导致经期延长,月经周期忽前忽后,精神状态不好。服用本品1月后,行经时间比以前有所缩短。服用2月后,痛经症状减轻,经期时间基本正常。继续服用本品3月后,经期恢复正常,精神好,医院检查子宫肌瘤有缩小迹象,病情稳定。
实例9:王远清,39岁。乳房有结节,易疲劳,晚上难入睡且易醒,睡眠质量差,经前有乳房胀痛,月经结束后好转。服用本品1月后,经前乳房胀痛有好转,晚上易入睡。继续服用1月后,经前乳房已不痛,睡眠质量好,皮肤变光滑,精力旺盛,不易疲劳。
实例10:曹敏佳,42岁。单位体检时发现有乳腺增生和子宫肌瘤,因症状不明显一直没有治疗,只是月经前一周乳房有胀痛,经后胀痛缓解。间断服用本品3个月,第二年单位体检时发现已无乳腺增生和子宫肌瘤。
附图说明
图1为浸膏制备流程图;
图2为颗粒剂制作流程图;
图3为胶囊剂制作流程图;
图4为片剂制作流程图。
具体实施方式
实施例1
一种治疗妇科疾病及具有美容作用的药食两用中药配方,其包含下述原料,按重量份数计:山药10份、夏枯草20份、党参15份、蒲公英10份、陈皮10份。
其颗粒剂制作步骤:称取以上五味药材,去除杂质后加5倍量水煎煮提取3次,每次1小时, 3次的煎液分别过滤后合并,将合并后的煎液浓缩成一定密度的浸膏,浸膏与适量辅料(糊精等)混匀、制成颗粒并干燥,按要求进行分装即得。
实施例2
一种治疗妇科疾病及具有美容作用的中药配方,其包含下述原料,按重量份数计:山药15份、夏枯草40份、党参20份、蒲公英25份,陈皮15份。
其胶囊剂制作:称取以上五味药材,去除杂质后加5倍量水煎煮提取3次,每次1小时, 3次的煎液分别过滤并合并,将合并后的煎液浓缩成一定密度的浸膏,浸膏与适量辅料(淀粉等)混匀、制粒、干燥后填充胶囊即得。
实施例3
一种治疗妇科疾病及具有美容作用的中药配方,其包含下述原料,按重量份数计:山药10份、夏枯草25份、党参15份、蒲公英20份,陈皮10份。
其片剂制作:称取以上五味药材,去除杂质后加5倍量水煎煮提取3次,每次1小时,3次的煎液分别过滤并合并,将合并后的煎液浓缩成一定密度的浸膏,浸膏与适量辅料(淀粉等)混匀、制粒、干燥、压片即得。
Claims (6)
1.一种治疗妇科疾病及具有美容作用的药食两用中药配方,其特征在于:其包含下述原料,按重量份数计:山药5~20份、夏枯草5~40份、党参5~30份、蒲公英5~20份、陈皮5~20。
2.根据权利要求1所述的一种疗妇科疾病及具有美容作用的药食两用中药配方,其特征在于:优选的,其包含下述原料,按重量份数计:山药10~15份、夏枯草10~30份、党参5~20份、蒲公英5~15份、陈皮10~15份。
3.根据权利要求1或2所述的一种疗妇科疾病及具有美容作用的药食两用中药配方,其特征在于:所述的药食两用的中药的剂型包括:颗粒剂、胶囊剂和片剂。
4.如权利要求3所述的一种疗妇科疾病及具有美容作用的药食两用中药配方的制备方法,其特征在于:它包括如下步骤:所述的颗粒剂制作步骤:按量称取以上五味药材,去除杂质后加水煎煮提取3次,3次的煎液分别过滤后合并,将合并后的煎液浓缩成浸膏,浸膏与辅料混匀制成颗粒并干燥,分装即得。
5.如权利要求3所述的一种疗妇科疾病及具有美容作用的药食两用中药配方的制备方法,其特征在于:它包括如下步骤:所述的胶囊剂制作:按量称取以上五味药材,去除杂质后加水煎煮提取3次, 3次的煎液分别过滤并合并,将合并后的煎液浓缩成浸膏,浸膏与辅料混匀、制粒、干燥后填充胶囊即得。
6.如权利要求3所述的一种疗妇科疾病及具有美容作用的药食两用中药配方的制备方法,其特征在于:它包括如下步骤:所述的片剂制作:按量称取以上五味药材,去除杂质后加水煎煮提取3次,煎液分别过滤并合并,将合并后的煎液浓缩成浸膏,浸膏与辅料混匀、制粒、干燥、压片即得。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610896099.7A CN106334065A (zh) | 2016-10-14 | 2016-10-14 | 一种治疗妇科疾病及具有美容作用的药食两用中药配方及生产工艺 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610896099.7A CN106334065A (zh) | 2016-10-14 | 2016-10-14 | 一种治疗妇科疾病及具有美容作用的药食两用中药配方及生产工艺 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106334065A true CN106334065A (zh) | 2017-01-18 |
Family
ID=57838798
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610896099.7A Pending CN106334065A (zh) | 2016-10-14 | 2016-10-14 | 一种治疗妇科疾病及具有美容作用的药食两用中药配方及生产工艺 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106334065A (zh) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107019209A (zh) * | 2017-03-24 | 2017-08-08 | 上海之彦网络科技有限公司 | 一种淮山功能性食品 |
| CN109663034A (zh) * | 2017-10-17 | 2019-04-23 | 云南苗心康生物科技有限公司 | 一种改善乳腺疾病的调理液 |
| CN117771308A (zh) * | 2023-11-24 | 2024-03-29 | 保定天浩制药有限公司 | 一种肝爽颗粒在制备治疗妇科疾病药物中的应用 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104435876A (zh) * | 2014-11-07 | 2015-03-25 | 郭根松 | 一种调节内分泌的中药组合物 |
-
2016
- 2016-10-14 CN CN201610896099.7A patent/CN106334065A/zh active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104435876A (zh) * | 2014-11-07 | 2015-03-25 | 郭根松 | 一种调节内分泌的中药组合物 |
Non-Patent Citations (2)
| Title |
|---|
| 哈孝贤: "《哈荔田》", 31 August 2014, 中国医药科技出版社 * |
| 钟赣生: "《中药学》", 31 May 2012, 中国中医药出版社 * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107019209A (zh) * | 2017-03-24 | 2017-08-08 | 上海之彦网络科技有限公司 | 一种淮山功能性食品 |
| CN109663034A (zh) * | 2017-10-17 | 2019-04-23 | 云南苗心康生物科技有限公司 | 一种改善乳腺疾病的调理液 |
| CN117771308A (zh) * | 2023-11-24 | 2024-03-29 | 保定天浩制药有限公司 | 一种肝爽颗粒在制备治疗妇科疾病药物中的应用 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN100339123C (zh) | 一种中药药酒及其制法 | |
| CN102133378B (zh) | 一种治疗乳腺癌的药物 | |
| CN101711850B (zh) | 一种治疗心肌缺血、心悸怔忡病证的中药组合物及制备方法 | |
| CN104013849A (zh) | 一种治疗高血压病的中药组合物及其制备方法 | |
| CN101856405B (zh) | 一种治疗2型糖尿病的药物组合物及其制备方法 | |
| CN1772157A (zh) | 用于产妇催乳强身中草药剂 | |
| CN106334065A (zh) | 一种治疗妇科疾病及具有美容作用的药食两用中药配方及生产工艺 | |
| CN101549078A (zh) | 一种用于治疗顽固性失眠的药物组合及其制备方法 | |
| CN103330826A (zh) | 一种治疗肺阴虚的中药组合物 | |
| CN103550710A (zh) | 一种治疗冠心病的葛根瓜蒌胸痹丸 | |
| CN103536849B (zh) | 治疗肺栓塞的药物及其制备方法 | |
| CN111358907A (zh) | 一种治疗失眠的药食同源中药配方颗粒及其制备方法 | |
| CN105796845A (zh) | 药物组合物在制备治疗女性更年期综合征药物中的用途 | |
| CN104984296A (zh) | 一种治疗女性更年期综合症的药物组合物及其制备方法 | |
| CN104606484A (zh) | 一种治疗气血虚的中药组合物及其制备方法 | |
| CN104258359A (zh) | 一种用于治疗妊娠反应的中药组合物及其制剂的制备方法 | |
| CN104042981A (zh) | 一种治疗产后便秘的药剂及制备方法 | |
| CN108938920A (zh) | 一种黄地强身酒及其制备方法 | |
| CN103006985A (zh) | 一种治疗失眠症的中药验方 | |
| CN105362630A (zh) | 一种治疗更年期综合症的药物组合物及其制备方法 | |
| CN103263580A (zh) | 一种治疗糖尿病的中药组合物 | |
| CN116549595B (zh) | 一种治疗儿童功能性消化不良的药物组合物及其制剂和应用 | |
| CN104042839A (zh) | 一种治疗花斑癣的中药组合物 | |
| CN1222364A (zh) | 辩证分型治疗癌症的内服、外敷、药膳系列药剂及制备方法 | |
| CN100493571C (zh) | 一种治疗心衰的药物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20170118 |